A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
NCT ID: NCT00156884
Last Updated: 2012-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
58 participants
INTERVENTIONAL
2003-08-31
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
NCT00024167
Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases
NCT00002503
Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer
NCT00003232
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00005960
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00005847
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
strontium-89
cisplatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* life expectancy \> 3 months,
* symptomatic from bone metastases
* radiologic evidence of metastatic bone disease
* stable level of pain control
* \>18 years
* ability to complete assessments
* prior treatment (chemo) \> 4 weeks previous
* discontinued anti-androgens for \> 4 weeks
Exclusion Criteria
* previous hemibody RT within 6 weeks
* previous cytotoxic chemotherapy within 4 weeks
* use of bisphosphonate medications within 4 weeks
* change in steroid dose within 4 weeks
* active uncontrolled infection
* impending or present spinal cord compression
* significant neurological disorder
* impending pathological fracture
* severe urinary incontinence
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Prostate Cancer Research Foundation of Canada
OTHER
Amersham Health
INDUSTRY
Alberta Health services
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bernie Eigl, MD
Role: PRINCIPAL_INVESTIGATOR
Alberta Cancerboard
Jackson Wu
Role: PRINCIPAL_INVESTIGATOR
Alberta Cancerboard
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tom Baker Cancer Centre
Calgary, Alberta, Canada
BC Cancer Agency
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GUPPS2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.